BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Summary by AI BETAClose X

BioNTech has successfully completed its acquisition of CureVac N.V., with approximately 86.75% of CureVac shares tendered in the exchange offer, and expects to finalize the compulsory acquisition of remaining shares in January 2026. This strategic move aims to enhance BioNTech's capabilities in mRNA design, delivery formulations, and manufacturing, further solidifying its position in the mRNA field and supporting its oncology strategy. CureVac will continue operating under its current processes while BioNTech conducts analyses to determine the future organizational and portfolio setup.

Disclaimer*

UK 100

Latest directors dealings